COVID-19 vaccination in Equatorial Guinea

Last updated

COVID-19 vaccination in Equatorial Guinea is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

Contents

COVID-19 vaccination in Equatorial Guinea
DateFebruary 15, 2021 (2021-02-15) – present
Location Equatorial Guinea
Cause COVID-19 pandemic
Participants293,702 total doses administered

Equatorial Guinea began its vaccination program on 15 February 2021, initially with 100,000 doses of the Sinopharm BIBP vaccine donated by China. [1] [2] [3]

Background

History

Timeline

February 2021

On 11 February 2021, 100,000 donated doses of the Sinopharm BIBP vaccine arrived in Equatorial Guinea from China. [4]

March 2021

By the end of the month 9,265 doses had been administered.

April 2021

By the end of the month 55,799 doses had been administered. 8,389 persons had been fully vaccinated.

May 2021

By the end of the month 219,677 doses had been administered. 71,598 persons had been fully vaccinated.

June 2021

On 16 June 2021, Equatorial Guinea buys 500,000 doses of the Sinopharm BIBP vaccine. [5] By the end of the month 260,528 doses had been administered. 111,343 persons had been fully vaccinated.

July 2021

By the end of the month 301,413 doses had been administered. 122,500 persons had been fully vaccinated.

August 2021

By the end of the month 331,807 doses had been administered. 141,326 persons had been fully vaccinated.

September 2021

By the end of the month 381,385 doses had been administered. 162,602 persons had been fully vaccinated.

October 2021

By the end of the month 426,780 doses had been administered. 186,670 persons (32% of the target population) had been fully vaccinated.

Progress

Cumulative vaccinations in Equatorial Guinea [6]

Related Research Articles

Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.

Sinopharm (company) Chinese state-owned enterprise

China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group, China Traditional Chinese Medicine, Shanghai Shyndec Pharmaceutical, and Beijing Tiantan Biological Products.

Sinopharm BIBP COVID-19 vaccine Vaccine against COVID-19

The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2 Vaccine, not to be confused with the similar product name of CoronaVac.

The COVID-19 vaccination program in the Philippines is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Zimbabwe

On 22 February 2021, Zimbabwe launched their national COVID-19 vaccination program using the Sinopharm BIBP vaccine. As of 26 November 2021, 3,756,498 people have received their first dose, and 2,786,979 people have received their second dose.

The COVID-19 vaccination in Morocco is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Angola is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

On 23 February 2021, Senegal began its national vaccination program against the COVID-19. As of 10 March, 68,205 people in Senegal have been able to be vaccinated.

COVID-19 vaccination in Africa Immunisation programme against COVID-19 in Africa

COVID-19 vaccination programs have begun in many countries and territories in Africa. As of 5 July 2021, vaccination campaigns had started in 51 African countries with 36.5 million people receiving at least one dose.

COVID-19 vaccination in Bhutan

Bhutan has promised a free COVID-19 vaccination to all of its citizens, both inside and outside the country. It started mass vaccinations on 27 March 2021.

COVID-19 vaccination in Vietnam Plan to immunize against COVID-19 in Vietnam

The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.

COVID-19 vaccination in Nigeria Plan to immunize against COVID-19

COVID-19 vaccination in Nigeria is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Vaccination began on 5 March 2021. As of 19 November 2021, 6,021,560 people have received their first dose a COVID-19 vaccine, and 3,369,628 people have received their second dose.

COVID-19 vaccination in Bangladesh

Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.

COVID-19 vaccination in Sri Lanka Plan to immunize against COVID-19

COVID-19 vaccination in Sri Lanka is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in response to the ongoing pandemic in the country. As of late July, the Sinopharm BIBP vaccine accounted for 78% of the total 13.8 million vaccines obtained by Sri Lanka to date. The United States donated over 1.5 million Moderna vaccine through COVAX.

COVID-19 vaccination in Burundi is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Cameroon is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Chad is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Egypt is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Comoros is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

References

  1. "owid/covid-19-data". GitHub. Retrieved 12 July 2021.
  2. "Equatorial Guinea: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data". covid19.who.int. Retrieved 12 July 2021.
  3. Reuters Staff (16 June 2021). "Equatorial Guinea buys 500,000 Sinopharm COVID-19 vaccines". Reuters. Retrieved 12 July 2021.
  4. "China donates 100,000 Covid vaccines to Equatorial Guinea". France24. 11 February 2021. Retrieved 21 July 2021.
  5. "Equatorial Guinea buys 500,000 Sinopharm COVID-19 vaccines". Reuters. 16 June 2021. Retrieved 22 July 2021.
  6. "COVID-19 Vaccine Statistics: As of July 17, 2021". covidvax.live. Retrieved 21 July 2021.